公开(公告)号：US09994865B2

公开(公告)日：2018-06-12

申请号：US14895125

申请日：2014-06-04

Applicant: The Johns Hopkins University ,  Virginia Commonwealth University

Inventor： Paul B. Fisher ,  Swadesh K. Das ,  Mitchell E. Menezes ,  Devanand Sarkar ,  Martin G. Pomper

IPC: A61K48/00 ,  C12N15/85 ,  C12N15/64 ,  C07K14/47 ,  G01N33/50 ,  G01N33/574 ,  A61K38/16 ,  A61K38/17 ,  A61K38/20 ,  A61K41/00 ,  A61K49/00 ,  A61N7/00 ,  C07K14/36 ,  C07K14/465 ,  C07K14/54 ,  C12N7/00 ,  C12N15/86 ,  C12N15/62 ,  B82Y5/00 ,  B82Y15/00

CPC classification number: C12N15/85 ,  A61K38/164 ,  A61K38/1703 ,  A61K38/20 ,  A61K41/0028 ,  A61K48/00 ,  A61K48/0058 ,  A61K48/0075 ,  A61K49/00 ,  A61N7/00 ,  A61N2007/0039 ,  B82Y5/00 ,  B82Y15/00 ,  C07K14/36 ,  C07K14/465 ,  C07K14/47 ,  C07K14/54 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/035 ,  C12N7/00 ,  C12N15/625 ,  C12N15/64 ,  C12N15/86 ,  C12N2710/10043 ,  C12N2710/10343 ,  C12N2799/02 ,  C12N2799/022 ,  C12N2800/22 ,  C12N2810/855 ,  C12N2830/002 ,  C12N2830/008 ,  G01N33/50 ,  G01N33/574

Abstract: The presently disclosed subject matter relates to compositions and methods directed to cancer theranostic nucleic acid constructs that permit simultaneous cancer-specific viral replication, expression of a diagnostic gene product, and expression of a therapeutic gene.

公开(公告)号：US20160130605A1

公开(公告)日：2016-05-12

申请号：US14895579

申请日：2014-06-04

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY

Inventor： Paul B. Fisher ,  Swadesh K. Das ,  Michelle D. Menezes ,  Devanand Sarkar

IPC: C12N15/86 ,  C12N15/85 ,  G01N33/50 ,  A61K49/00

CPC classification number: C12N15/86 ,  A61K49/0008 ,  C07K14/47 ,  C12N15/85 ,  C12N15/8509 ,  C12N2710/10331 ,  C12N2710/10345 ,  C12N2830/008 ,  C12N2830/85 ,  G01N33/5088 ,  G01N33/57492

Abstract: Recombinant vectors in which expression of one or more elements (e.g. genes required for viral replication, detectable imaging agents, therapeutic agents, etc.) is driven by an mda-9/syntenin (mda-9) cancer selective promoter are provided, as are cells and transgenic animals that contain such vectors. The vectors are used in cancer therapy and/or diagnostics, especially to visualize (image) and treat metastasis (including in rapid in vitro assays), and the transgenic mice are used to monitor cancer progression and/or the efficacy of candidate therapeutic agents in screening assays.

Abstract translation: 提供其中一种或多种元件（例如病毒复制所需的基因，可检测的成像剂，治疗剂等）由mda-9 / syntenin（mda-9）癌选择性启动子驱动的重组载体，如 细胞和含有这种载体的转基因动物。 这些载体用于癌症治疗和/或诊断，特别是可视化（图像）和治疗转移（包括在快速体外测定中），并且转基因小鼠用于监测候选治疗剂的癌症进展和/或功效 筛选试验。

公开(公告)号：US20190290711A1

公开(公告)日：2019-09-26

申请号：US16369886

申请日：2019-03-29

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY

Inventor： Paul Fisher ,  Devanand Sarkar ,  Paul Dent

IPC: A61K35/768 ,  C12N7/00 ,  A61K31/166 ,  A61K31/404 ,  A61K45/06 ,  A61K39/00 ,  C12N15/86

Abstract: A tropism modified cancer terminator virus (Ad.5/3-CTV; Ad.5/3-CTV-M7) has been found to have infectivity that is Coxsackie Adenoviral Receptor (CAR) independent. The Ad.5/3-CTV (Ad.5/3-CTV-M7) may be used alone or in combination with other therapeutic agents such as agents that augment reactive oxygen (ROS) production, HDAC inhibitors, MCL-1 inhibitors and Bcl-2 inhibitors to treat a variety of cancers particularly including malignant glioma (GBM), renal cancer, prostate cancer, and colorectal cancer.

公开(公告)号：US09750823B2

公开(公告)日：2017-09-05

申请号：US14895247

申请日：2014-06-04

Applicant: Virginia Commonwealth University

Inventor： Paul B. Fisher ,  Swadesh K. Das ,  Rupesh Dash ,  Devanand Sarkar ,  Siddik Sarkar ,  Jolene Windle

IPC: A61K48/00 ,  A61K47/00 ,  A61K49/00 ,  C12N15/00 ,  C12N5/00 ,  A01K67/027 ,  A61K35/761 ,  C12N15/86 ,  C12N15/85

CPC classification number: A61K48/0058 ,  A01K67/0275 ,  A01K2207/12 ,  A01K2217/052 ,  A01K2217/206 ,  A01K2227/105 ,  A01K2267/0331 ,  A01K2267/0393 ,  A61K35/761 ,  A61K49/0008 ,  A61K49/005 ,  C12N15/86 ,  C12N2015/8536 ,  C12N2015/8572 ,  C12N2710/10332 ,  C12N2830/008 ,  C12N2830/34

Abstract: Recombinant vectors in which expression of one or more elements (e.g. genes required for viral replication, detectable imaging agents, therapeutic agents, etc.) is driven by a truncated CCN 1 cancer selective promoter (tCCN1-Prom) are provided, as are cells and transgenic animals that contain such vectors. The vectors are used in cancer therapy and/or diagnostics, and the transgenic mice are used to monitor cancer progression, e.g. in screening assays.

公开(公告)号：US20160108429A1

公开(公告)日：2016-04-21

申请号：US14895125

申请日：2014-06-04

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY ,  THE JOHNS HOPKINS UNIVERSITY

Inventor： Paul B. FISHER ,  Swadesh K. Das ,  Mitchell E. MENEZES ,  Devanand Sarkar ,  Martin G. POMPER

IPC: C12N15/85 ,  A61K38/20 ,  C07K14/465 ,  C07K14/36 ,  C07K14/54 ,  A61N7/00 ,  A61K48/00 ,  A61K38/17 ,  A61K38/16 ,  C12N15/86 ,  C12N7/00 ,  A61K49/00 ,  A61K41/00

CPC classification number: C12N15/85 ,  A61K38/164 ,  A61K38/1703 ,  A61K38/20 ,  A61K41/0028 ,  A61K48/00 ,  A61K48/0058 ,  A61K48/0075 ,  A61K49/00 ,  A61N7/00 ,  A61N2007/0039 ,  B82Y5/00 ,  B82Y15/00 ,  C07K14/36 ,  C07K14/465 ,  C07K14/47 ,  C07K14/54 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/035 ,  C12N7/00 ,  C12N15/625 ,  C12N15/64 ,  C12N15/86 ,  C12N2710/10043 ,  C12N2710/10343 ,  C12N2799/02 ,  C12N2799/022 ,  C12N2800/22 ,  C12N2810/855 ,  C12N2830/002 ,  C12N2830/008 ,  G01N33/50 ,  G01N33/574

Abstract: The presently disclosed subject matter relates to compositions and methods directed to cancer theranostic nucleic acid constructs that permit simultaneous cancer-specific viral replication, expression of a diagnostic gene product, and expression of a therapeutic gene.

Abstract translation: 目前公开的主题涉及涉及癌细胞核酸构建体的组合物和方法，其允许同时进行癌症特异性病毒复制，诊断基因产物的表达和治疗基因的表达。

公开(公告)号：US20160008413A1

公开(公告)日：2016-01-14

申请号：US14650775

申请日：2013-12-10

Applicant: Virginia Commonwealth University

Inventor： Paul Fisher ,  Devanand Sarkar ,  Paul Dent

IPC: A61K35/768 ,  A61K31/404 ,  A61K31/166 ,  C12N7/00 ,  A61K45/06

CPC classification number: A61K35/768 ,  A61K31/166 ,  A61K31/404 ,  A61K39/0011 ,  A61K45/06 ,  A61K2039/5254 ,  A61K2039/55511 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/10032 ,  C12N2710/10321 ,  C12N2710/10332 ,  C12N2710/10343 ,  C12N2710/10371

Abstract: A tropism modified cancer terminator virus (Ad.5/3-CTV; Ad.5/3-CTV-M7) has been found to have infectivity that is Coxsackie Adenoviral Receptor (CAR) independent. The Ad.5/3-CTV (Ad.5/3-CTV-M7) may be used alone or in combination with other therapeutic agents such as agents that augment reactive oxygen (ROS) production, HDAC inhibitors, MCL-1 inhibitors and Bcl-2 inhibitors to treat a variety of cancers particularly including malignant glioma (GBM), renal cancer, prostate cancer, and colorectal cancer.

Abstract translation: 已经发现向性改良的癌症终止子病毒（Ad.5 / 3-CTV; Ad.5 / 3-CTV-M7）具有独立的柯萨奇腺病毒受体（CAR）感染性。 Ad5 / 3-CTV（Ad.5 / 3-CTV-M7）可以单独使用或与其他治疗剂组合使用，例如增加活性氧（ROS）产生的药物，HDAC抑制剂，MCL-1抑制剂和 用于治疗各种癌症的Bcl-2抑制剂，特别包括恶性胶质瘤（GBM），肾癌，前列腺癌和结肠直肠癌。